Daxor announces study published on its Blood Volume Analysis

Daxor (DXR) announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor’s Blood Volume Analysis, BVA. The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment. The study revealed several critical findings: Commonly used hemodynamic pressure measures are inaccurate surrogates compared to direct blood volume analysis with Daxor BVA; BVA enables more accurate diagnosis of true anemia which is a key guideline target of care; Sex-specific volume differences as illuminated by BVA require individualized treatment approaches.